CoChat

Steroid Avoidance or Withdrawal After Renal Transplantation Increases the Risk of Acute Rejection but Decreases Cardiovascular Risk. A Meta-Analysis

Knight, Simon R., Morris, Peter J. · 2010 · Transplantation

The DOI matches its Crossref record; 112 of the 113 references it cites were found in a registry or an index.

Abstract

Introduction The morbidity related to long-term steroid therapy has led to continued interest in withdrawal of steroids from immunosuppressant regimens after renal transplantation. A number of recent trials have provided long-term information regarding the risks and benefits of steroid avoidance or withdrawal (SAW). Methods A literature search was performed using Ovid Medline, Embase, the Cochrane Library, and the Transplant Library. Randomized controlled trials comparing a maintenance steroid group with complete avoidance or withdrawal of steroids were selected. All studies were assessed for methodological quality. Trials were pooled by meta-analysis to provide summary effects (relative risk [RR] or weighted mean difference) with 95% confidence intervals (CI). Results Thirty-four studies including 5,637 patients met the inclusion criteria. SAW regimens significantly increased the risk of acute rejection (AR) over maintenance steroids (RR 1.56, CI 1.31-1.87, P Conclusion Despite an increase in the risk of AR with SAW protocols, there is only a small effect on graft function with no measurable effect on graft or patient survival. There are significant benefits in cardiovascular risk profiles after SAW. SAW protocols would seem justified with current immunosuppressive protocols in low-risk recipients.

Overview

Integrity signals

Registry

Crossref · 10.1097/tp.0b013e3181c518cc

Cites

112 of 112 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 112 references

Research works printed but not linked: 41

  1. Tan, 2006, Safety and efficacy of steroid withdrawal in modern triple immunosuppressant: A systematic review [Chinese]., Chin J Evid Based Med, 6, 273
  2. Vincenti, 2005, 3 months interim results of a 12-month study with enteric-coated mycophenolate sodium (EC-MPS, Myfortic®), basiliximab, and neoral C-2 comparing different steroid protocols in de novo kidney recipients [abstract]., J Am Soc Nephrol, 16, 236a
  3. Walker, 2005, Preliminary results of a 12-month study with enteric-coated mycophenolate sodium (EC-MPS), basiliximab, and neoral C-2 comparing two investigational steroid regimens (without steroids or short-term use of steroids) with standard steroid treatment in de novo kidney recipients [abstract]., Nephrology, 10, A214
  4. Vincenti, 2006, Metabolic effects of steroid avoidance or early steroid withdrawal: 12-month results of a randomised trial in de novo renal transplant patients receiving cyclosporine, enteric-coated mycophenolate sodium (EC-MPS) and basiliximab [abstract]., Am J Transplant, 6, 483
  5. Schena, 2006, 12-month results of a prospective, randomised trial of steroid avoidance, steroid withdrawal and standard steroids in de novo renal transplant patients receiving cyclosporine, enteric-coated mycophenolate sodium (EC-MPS) and basiliximab [abstract]., Am J Transplant, 6, 84
  6. Vincenti, 2005, Preliminary 3-month results comparing immunosuppressive regimens of enteric-coated mycophenolate sodium (EC- MPS) without steroids vs short-term use of steroids vs standard steroid treatment including basiliximab, and neoral C-2 in de novo kidney recipients abstract., Am J Transplant, 5, 548
  7. Walker, 2007, Comparison of metabolic parameters in renal transplant patients randomised to steroid avoidance, steroid withdrawal or standard steroids within a 12 month randomised multicentre trial [abstract]., Transplant Soc Aust N Z, 32
  8. Ing, 2007, Bone mineral density changes in a prospective randomized trial of steroid withdrawal in kidney transplant recipients abstract., Am J Transplant, 7, 310
  9. Stiller, 1983, The requirements for maintenance steroids in cyclosporine-treated renal transplant recipients., Transplant Proc, 15, 2490
  10. De Vecchi, 1985, Need for steroid in cyclosporine (Cy) treated cadaveric renal transplant recipients (pts) [abstract]., Kidney Int, 28, 394
  11. Griffin, 1986, Renal transplantation without steroids: A controlled clinical trial., Transplant Proc, 18, 797
  12. Nott, 1985, Low-dose steroids do not augment cyclosporine immunosuppression but do diminish cyclosporine nephrotoxicity., Transplant Proc, 17, 1289
  13. Johnson, 1990, Prospective trials with cyclosporine monotherapy in cadaver renal transplantation., J Nephrol, 3, 47
  14. Tarantino, 2000, Long-term results of a randomized trial of 3 cyclosporine (CSA) regimens in cadaveric kidney allografts (TXC) [abstract]., Nephrol Dial Transplant, 15, 250
  15. Klinger, 2003, Large, prospective study evaluating steroid-free immunosuppression with tacrolimus/basiliximab and tacrolimus/MMF compared with tacrolimus/MMF/steroids in renal transplantation [abstract]., Nephrol Dial Transplant, 18, 788
  16. Kramer, 2003, Two steroid-free immunosuppressive regimens (basiliximab/tacrolimus and tacrolimus/MMF) in comparison to tacrolimus/MMF/steroid therapy after renal transplantation [abstract]., J Am Soc Nephrol, 14, 9a
  17. Kramer, 2004, 1-year follow-up of two steroid-free immunosuppressive regimens—Basiliximab/Tacrolimus and tacrolimus/MMF—In comparison to tacrolimus/MMF/steroids after renal transplantation [abstract]., J Am Soc Nephrol, 15, 289a
  18. Vitko, 2003, Comparison of two steroid-free regimens—Basiliximab/Tacrolimus and Tacrolimus/MMF—With Tacrolimus/MMF/Steroid Therapy After Renal Transplantation [abstract]., Am J Transplant, 3, 312
  19. Pankewycz, 2004, The clinical benefits of early steroid withdrawal (7 days) and utility of protocol biopsies at 1, 6 and 12 months in guiding steroid-free immunosuppressive therapy after renal transplantation [abstract]., Am J Transplant, 4, 579
  20. Pankewyez, 2003, Induction immunosuppression for renal transplantation using thymoglobulin, FK506 and mycophenolate mofetil allows for safe steroid withdrawal and eliminates the need for early protocol biopsies [abstract]., Am J Transplant, 3, 478
  21. Gaber, 2006, Characteristics of rejection in renal allografts following early corticosteroid withdrawal in a randomized controlled clinical trial: Results of a 3 year follow-up [abstract]., Transplantation, 82, 178
  22. Pirsch, 2006, Effect of steroid withdrawal on new onset diabetes after transplant: Results of a randomized double blinded placebo controlled trial [abstract]., Transplantation, 82, 355
  23. Woodle, 2007, A randomized double blind, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroids: Four year results [abstract]., Am J Transplant, 7
  24. Woodle, 2006, Comparison of T cell depleting and non-t cell depleting antibody induction therapy for early corticosteroid withdrawal regimens abstract., Transplantation, 82, 353
  25. Woodle, 2008, A randomsied double blind, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroids: Five year results., Am J Transplant, 8, 300
  26. Nematalla, 2007, Improving quality of life after steroid avoidance immunosuppression regimen in live donor renal allotransplant recipients—A prospective randomized controlled study single center experience (Two year follow up) [abstract]., Transpl Int, 20, 134
  27. Aswad, 1998, Steroid withdrawal in living related kidney transplant patients receiving FK506 [abstract]., Nephrol Dial Transplant, 13, A285
  28. Burke, 2001, Double-blind, placebo-controlled trial of steroid withdrawal in kidney transplant recipients with a cyclosporine/mycophenolate regimen-three year follow up [abstract]., Am J Transplant, 1, 296
  29. Francos, 2002, Double-blind, placebo-controlled, 3 year study of steroid withdrawal using a neoral and mycophenylate mofetil (MMF)-based immunosuppressive regimen in primary renal transplant recipients [abstract]., Am J Transplant, 2, 172
  30. Boletis, 2002, Steroids withdrawal in renal transplant recipients: A randomized controlled study [abstract]., Nephrol Dial Transplant, 17, 312
  31. Smak Gregoor, 2001, A prospective randomised study of withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone: 18 months follow-up data [abstract]., Am J Transplant, 1, 246
  32. Smak Gregoor, 2003, Long-term results of a randomized, prospective study after withdrawal of cyclosporine or prednisone in renal transplant recipients treated with mycophenolate mofetil, cyclosporine, and prednisone [abstract]., Am J Transplant, 3, 217
  33. Jindal, 2002, Reduction of high cholesterol levels by early withdrawal of steroids from a tacrolimus-based triple regimen [abstract]., Am J Transplant, 2, 190
  34. Pascual, 2004, Long-term efficacy and safety of steroid withdrawal in tacrolimus-treated renal transplant recipients: Results of a 3 year followup., Am J Transplant, 4, 578
  35. van Hooff, 2001, First, large, prospective study of a controlled withdrawal of steroids or MMF following three months of tacrolimus/MMF/steroid therapy abstract., J Am Soc Nephrol, 12, 920a
  36. Dudley, 1994, Effect of steroid withdrawal on graft function in renal transplant recipients [abstract]., Nephrol Dial Transplant, 9, 1672
  37. Hollander, 1996, Late prednisone withdrawal in renal transplant patients [abstract]., J Am Soc Nephrol, 7, 1911
  38. Matl, 2000, Withdrawal of steroids from the triple-drug therapy in renal transplant patients., Casopis Lekaru Ceskych, 139, 115
  39. Matl, 1998, Withdrawal of steroids from triple drug therapy in renal transplant patients [abstract]., Nephrol Dial Transplant, 13, A256
  40. Farmer, 2001, What is the value of short synacthen tests in predicting the ease of steroid withdrawal in renal transplant recipients? A randomised controlled trial [abstract]., Am J Transplant, 1, 190
  41. Akin, 2004, Five year follow-up after steroid withdrawal demonstrates no evidence of worsening renal function [abstract]., Am J Transplant, 4, 298

Cited by

Items 101–200 of 264

Metadata

Authors
Knight, S. R., & Morris, P. J.
Affiliations
University of London (GB)
Corresponding author
Morris, Peter J.
Venue
Transplantation
Published
2010-01-15
Volume
89
Issue
1
Pages
1-14
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2006211317
Cited by
265
References
113
Citations by year
2026: 1 · 2025: 5 · 2024: 8 · 2023: 14 · 2022: 11 · 2021: 14 · 2020: 10 · 2019: 15 · 2018: 13 · 2017: 17 · 2016: 25 · 2015: 20 · 2014: 26 · 2013: 16 · 2012: 21
FWCI
4.58
Type
journal article
Language
en
Open access
closed
Locations
  • Transplantation (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Transplantation › Renal Transplantation Outcomes and Treatments
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Health Sciences › Medicine › Nephrology › Renal and Vascular Pathologies
Keywords
steroid avoidance, corticosteroid withdrawal, kidney transplantation, acute rejection, corticosteroid-sparing immunosuppression, cardiovascular risk, hypertension, new-onset diabetes, hypercholesterolemia, graft survival, patient survival, serum creatinine
MeSH terms
Adrenal Cortex Hormones, Cardiovascular Diseases, Graft Rejection, Humans, Immunosuppressive Agents, Meta-Analysis as Topic, Kidney Transplantation, Survivors, Patient Selection

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.